Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

Not Applicable

• Conditions: Prostate Cancer
• Interventions: Device: Focal-Fusion Bx

• Registration Number: NCT02524860
• Lead Sponsor: Focal Healthcare Inc.

Brief Summary

The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.

Detailed Description

The objective of this study is to determine the effectiveness of the Focal-Fusion Bx device at finding clinically relevant prostate cancer.

A multiparametric MRI examination will be carried out prior to study enrollment. Probable cancerous regions (regions of interest, ROI) will be identified, and these ROIs will be used as targets during the biopsy.

Three prostate sampling methods will be conducted in the same session on all patients. These include:

i) Focal-Fusion Bx targeted biopsy ii) Cognitive fusion targeted biopsy and iii) Systematic (untargeted) biopsy. Trans-rectal ultrasound (TRUS) imaging will be conducted with BK Flex Focus Ultrasound system (Analogic Corporation, Peabody, MA).

Primary hypothesis: The technique used to acquire the biopsy samples will impact the proportion of clinically relevant cancers by improving the specificity of detecting clinically significant cancers. It is hypothesized that Focal-Fusion Bx biopsies will diagnose more high risk cancers and fewer low-risk cancers than non-targeted systematic biopsies.

Study Timeline

• Study First Submitted: 2015-08-14
• Study First Submitted QC: 2015-08-14
• Study First Posted: 2015-08-17
• Study Start: 2015-09
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-14
• Last Update Posted: 2017-03-16
• Primary Completion: 2017-09
• Study Completion: 2017-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• Adult male subjects up to 80 years of age
• Candidates for fusion biopsy
• Elevated PSA levels
• MP-MRI with lesions having a Prostate Imaging Reporting and Data System (PI-RADS) score greater than or equal to 3 (determined by a trained radiologist)
• Subject is willing and able to read, understand and sign the Informed Consent Form document

Exclusion Criteria

• Previous treatment for prostate cancer
• Any contraindication to a standard TRUS prostate biopsy procedure
• Refusal to sign the Informed Consent document

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MRI-ultrasound fusion device	Focal-Fusion Bx	Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging

Primary Outcome Measures

Name	Time	Method
Proportion of biopsy cores positive for clinically significant cancer.	12 months

Secondary Outcome Measures

Name	Time	Method
Number of men diagnosed with clinically significant and clinically insignificant cancer.	12 months

Trial Locations

Locations (1)

Urology Treatment Center (division of 21st Century Oncology, Inc.); 🇺🇸 Sarasota, Florida, United States